Hypervision Surgical (“Hypervision”), a pioneer in real-time hyperspectral imaging for surgery, today announced the successful closing of its oversubscribed £17 million Series A financing round, led by Heal Capital with participation from Angelini Ventures, IP Group, and Daycrest. The round also includes follow-on investment from existing investors HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures.
The financing further includes strategic investment from the SINC Fund managed by SAGES Ingenuity, the for-profit innovation arm subsidiary of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) – a leading global surgical society – and Macmillan Cancer Support, the UK’s leading cancer charity. Their participation represents strong validation from both the global surgical community and leading cancer organisations.
The Series A financing will accelerate commercial deployment of Hypervision’s Hyperspectral Intelligence® platform, expand clinical adoption, and advance development of the company’s next-generation hyperspectral sensing technology – co-developed with imec, the world’s leading independent nanoelectronics R&D hub. This strategic venture partnership includes design, development and manufacturing of Hypervision’s new spectral sensor at imec.
This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery – giving surgeons real-time insights into tissue that were previously impossible to access.
— Michael Ebner, CEO and co-founder of Hypervision Surgical
Surgical AI has made impressive progress using conventional cameras, but it ultimately faces a ceiling – it captures how tissue looks, not what is happening beneath the surface. Hypervision removes that limitation by delivering real-time, quantitative insights into tissue physiology at the pixel level. We believe this represents the sensing layer on which the next generation of surgical systems will be built – one that will make surgery measurably safer. That’s why we are proud to lead this round.
— Christian Lautner, Founding Managing Partner, Heal Capital
The SAGES Investment Network Collaborative (SINC) is thrilled to have had the chance to review and join the investment opportunity that Hypervision represents. Enhancing the capabilities around non-contrast visualization is truly a step forward in smarter imaging.
— Steven D. Schwaitzberg, MD, President of SAGES Ingenuity
As part of the financing, Rick Mangat joins Hypervision’s Board of Directors. A pioneer in surgical imaging and the founder of NOVADAQ (acquired by Stryker), his fluorescence imaging-based technology widely powers leading commercial vision systems for robotic, laparoscopic, and open surgery.
Building a New Layer of Surgical Intelligence
Hyperspectral Intelligence®: A new layer of surgical intelligence. Hypervision’s spectral chip and AI seamlessly integrate into existing vision systems, delivering quantitative tissue insights beyond conventional, subjective vision. As a software-centric solution, it enables scalable, data-driven decision support – adding an objective layer of intelligence during surgery.
Despite advances in digital and robotic surgery, surgeons still rely largely on subjective visual assessment to guide critical intraoperative decisions. Hypervision is addressing this fundamental limitation with the world’s first regulatory-cleared real-time hyperspectral imaging platform for surgery, delivering quantitative tissue insights beyond human vision.
At the core of the company’s approach is Hyperspectral Intelligence®, Hypervision’s platform technology combining proprietary on-chip spectral sensing, patented AI analytics, and a cloud-scalable architecture. Together, these technologies transform surgical imaging into real-time, data-driven decision support, generating previously invisible pixel-level insights into tissue physiology and composition during surgery.
This architecture creates a scalable intelligence layer for surgical vision systems across open, minimally invasive, robotic, and microscopic platforms, transforming conventional surgical cameras into data-rich diagnostic tools. In doing so, Hypervision shifts surgical imaging from a static, hardware-limited model to a flexible, software-centric paradigm designed for continuous evolution.
Strong Clinical and Strategic Momentum
HYPERSNAP®, Hypervision’s first commercial surgical system, represents the initial clinical deployment of Hyperspectral Intelligence®. It is built on the NVIDIA IGX platform, leveraging its high-performance edge computing capabilities to power real-time AI inference in the operating room, and its software-defined architecture to support flexible integration and deployment models. HYPERSNAP® is certified in the UK and cleared by the US FDA for open and minimally invasive general surgery, providing continuous, dye-free measurement of tissue oxygenation while preserving natural colour information as seen by the human eye. As part of its clearance, the FDA issued a new product code for AI/ML-based real-time video augmentation in imaging systems used in endoscopic or open surgical procedures, recognising Hypervision’s novel approach to data-driven surgical vision.
HYPERSNAP®, Hypervision’s first commercial surgical system, shown here in an operating theatre environment, represents the initial clinical deployment of the Hyperspectral Intelligence® platform — a fully certified laparoscopic vision stack designed for seamless integration into surgical workflows. It is certified for use in open and minimally invasive general surgery in both the UK and the USA.
By capturing spectral signatures invisible to the human eye, HYPERSNAP® enables surgeons to assess tissue viability in real time during critical steps such as bowel transection for cancer patients. This capability may help reduce anastomotic leakage, one of the most severe complications in gastrointestinal surgery. Anastomotic leaks occur in up to 15% of colorectal procedures and are associated with cancer recurrence, emergency reinterventions, prolonged ICU stays, and costs exceeding $50,000 per case.
In colorectal surgery today, bowel viability is assessed subjectively through visual inspection. Hypervision’s technology extends surgical vision beyond the limits of the human eye. Its first certified product provides real-time quantitative tissue oxygenation (StO₂) alongside conventional colour vision. By providing an objective measure of StO₂, a hallmark of tissue perfusion, it may help surgeons select a more precise transection line within bowel tissue with better healing potential, potentially reducing the risk of complications such as anastomotic leakage.
HYPERSNAP® was previously selected for the FDA’s Safer Technologies Program (STeP), highlighting its potential to improve the safety of existing surgical treatments. Early clinical evaluations in colorectal surgery are underway with selected clinical partners in the UK, with initial results accepted for presentation at the SAGES Annual Meeting, one of the world’s leading surgical conferences.
Looking ahead, the company aims to integrate Hyperspectral Intelligence® across laparoscopic, robotic, microscopic, and endoscopic surgical platforms – enabling data-rich surgical vision across hundreds of millions of procedures annually.
You can find our official press release here with exclusive coverage by Sky News.